ANDERSON CLINICAL RESEARCH
- Type
- Non-covered entity
- Where
- REDLANDS, CA
- Received
- $1,534,209 in 322 records, 2019 to 2025 ($0 general, $1,534,209 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | Research payment | 34 | $501,456 |
| 2024 | Research payment | 2 | $3,821 |
| 2023 | Research payment | 5 | $16,658 |
| 2022 | Research payment | 8 | $20,303 |
| 2021 | Research payment | 35 | $60,800 |
| 2020 | Research payment | 56 | $111,781 |
| 2019 | Research payment | 182 | $819,388 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Axsome Therapeutics, Inc. | 23 | $433,016 | 2025 |
| Alkermes, Inc. | 171 | $347,377 | 2019–2023 |
| Biogen, Inc. | 2 | $258,724 | 2019–2020 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $110,999 | 2019 |
| Allergan, Inc. | 14 | $81,604 | 2019–2021 |
| Genentech, Inc. | 10 | $75,349 | 2019 |
| Eli Lilly and Company | 32 | $67,443 | 2019–2025 |
| Eisai Inc. | 26 | $48,914 | 2019 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $41,454 | 2019–2021 |
| E.R. Squibb & Sons, L.L.C. | 2 | $40,377 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $26,523 | 2025 |
| Teva Pharmaceuticals USA, Inc. | 1 | $1,500 | 2019 |
| Boehringer Ingelheim RCV GmbH & Co KG | 27 | $926 | 2019–2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 322 | $1,534,209 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-11 | Axsome Therapeutics, Inc. | $21,987 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-12-11 | Axsome Therapeutics, Inc. | $35 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-11-14 | Axsome Therapeutics, Inc. | $30,234 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-11-14 | Axsome Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-11-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,900 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 | |
| 2025-10-17 | Axsome Therapeutics, Inc. | $36,948 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-10-17 | Axsome Therapeutics, Inc. | $315 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-10-13 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $4,298 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 | |
| 2025-10-06 | E.R. Squibb & Sons, L.L.C. | $38,940 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar | 2025 | |
| 2025-10-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,478 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 | |
| 2025-10-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $114 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 | |
| 2025-09-15 | Axsome Therapeutics, Inc. | $48,395 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-09-15 | Axsome Therapeutics, Inc. | $4,835 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-09-08 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $11,290 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 | |
| 2025-09-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 | |
| 2025-08-26 | E.R. Squibb & Sons, L.L.C. | $1,437 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Kar | 2025 | |
| 2025-08-13 | Axsome Therapeutics, Inc. | $40,447 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-08-13 | Axsome Therapeutics, Inc. | $140 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-08-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $7,382 | Research payment | Cash or cash equivalent | A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of IT | 2025 | |
| 2025-07-23 | Axsome Therapeutics, Inc. | $53,023 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-07-23 | Axsome Therapeutics, Inc. | $240 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-06-13 | Axsome Therapeutics, Inc. | $57,188 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-06-13 | Axsome Therapeutics, Inc. | $2,070 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-05-16 | Axsome Therapeutics, Inc. | $43,469 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-05-16 | Axsome Therapeutics, Inc. | $105 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-04-16 | Axsome Therapeutics, Inc. | $45,164 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-04-16 | Axsome Therapeutics, Inc. | $1,106 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-03-24 | Axsome Therapeutics, Inc. | $14,921 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-02-25 | Eli Lilly and Company | $607 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2025 | |
| 2025-02-18 | Axsome Therapeutics, Inc. | $22,814 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-02-14 | Axsome Therapeutics, Inc. | $182 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-02-12 | Eli Lilly and Company | $931 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2025 | |
| 2025-01-14 | Axsome Therapeutics, Inc. | $8,688 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2025-01-14 | Axsome Therapeutics, Inc. | $600 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | 2025 | |
| 2024-01-31 | Eli Lilly and Company | $1,924 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 | |
| 2024-01-17 | Eli Lilly and Company | $1,896 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2024 | |
| 2023-11-24 | Alkermes, Inc. | $5,989 | Research payment | Cash or cash equivalent | LYBALVI Drug, CNS | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2023 |
| 2023-05-10 | Eli Lilly and Company | $663 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY AND EFFICACY OF SUBCUTANEOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2023 | |
| 2023-01-26 | Eli Lilly and Company | $5,002 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER | 2023 | |
| 2023-01-26 | Eli Lilly and Company | $3,134 | Research payment | In-kind items and services | A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | 2023 | |
| 2023-01-13 | Eli Lilly and Company | $1,867 | Research payment | In-kind items and services | A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIM | 2023 | |
| 2022-07-06 | Eli Lilly and Company | $6,046 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2022 | |
| 2022-06-24 | Alkermes, Inc. | $649 | Research payment | Cash or cash equivalent | LYBALVI Drug, CNS | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2022 |
| 2022-03-25 | Alkermes, Inc. | $1,848 | Research payment | Cash or cash equivalent | LYBALVI Drug, CNS | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2022 |
| 2022-03-08 | Eli Lilly and Company | $31 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2022 | |
| 2022-01-28 | Alkermes, Inc. | $1,351 | Research payment | Cash or cash equivalent | LYBALVI Drug, CNS | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2022 |
| 2022-01-20 | Eli Lilly and Company | $7,031 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2022 | |
| 2022-01-11 | Eli Lilly and Company | $2,389 | Research payment | In-kind items and services | A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | 2022 | |
| 2022-01-05 | Eli Lilly and Company | $957 | Research payment | In-kind items and services | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS | 2022 | |
| 2021-12-31 | Allergan, Inc. | $689 | Research payment | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-12-31 | Allergan, Inc. | $525 | Research payment | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-12-31 | Allergan, Inc. | $200 | Research payment | In-kind items and services | A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATO | 2021 | |
| 2021-12-23 | Alkermes, Inc. | $3,034 | Research payment | Cash or cash equivalent | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2021 |
| 2021-11-26 | Alkermes, Inc. | $1,404 | Research payment | Cash or cash equivalent | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2021 |
| 2021-11-24 | Eli Lilly and Company | $195 | Research payment | In-kind items and services | A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS | 2021 | |
| 2021-10-29 | Alkermes, Inc. | $2,538 | Research payment | Cash or cash equivalent | OLANZAPINE Drug, CNS | A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Sc | 2021 |
| 2021-10-25 | Alkermes, Inc. | $22,239 | Research payment | In-kind items and services | LYBALVI Drug, CNS | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 |
| 2021-10-01 | Alkermes, Inc. | $3,034 | Research payment | Cash or cash equivalent | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-09-30 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-08-27 | Alkermes, Inc. | $3,511 | Research payment | Cash or cash equivalent | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-08-23 | Eli Lilly and Company | $6 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2021 | |
| 2021-08-17 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-08-17 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $906 | Research payment | Cash or cash equivalent | PoCC dose finding in Mild to Moderate AD | 2021 | |
| 2021-05-10 | Eli Lilly and Company | $65 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2021 | |
| 2021-05-10 | Eli Lilly and Company | $7 | Research payment | In-kind items and services | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2021 | |
| 2021-05-03 | Eli Lilly and Company | $4,916 | Research payment | In-kind items and services | A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | 2021 | |
| 2021-04-27 | Eli Lilly and Company | $75 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLA | 2021 | |
| 2021-04-26 | Eli Lilly and Company | $75 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-04-08 | Eli Lilly and Company | $65 | Research payment | In-kind items and services | A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES A | 2021 | |
| 2021-04-08 | Eli Lilly and Company | $61 | Research payment | In-kind items and services | A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH | 2021 | |
| 2021-04-08 | Eli Lilly and Company | $15 | Research payment | In-kind items and services | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUAT | 2021 | |
| 2021-04-08 | Eli Lilly and Company | $4 | Research payment | In-kind items and services | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2021 | |
| 2021-03-26 | Alkermes, Inc. | $1,404 | Research payment | Cash or cash equivalent | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-02-26 | Alkermes, Inc. | $3,293 | Research payment | Cash or cash equivalent | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-01-29 | Eli Lilly and Company | $7,505 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2021 | |
| 2021-01-29 | Alkermes, Inc. | $3,075 | Research payment | Cash or cash equivalent | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-01-29 | Eli Lilly and Company | $703 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2021 | |
| 2021-01-13 | Alkermes, Inc. | $194 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-01-13 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-01-13 | Alkermes, Inc. | $138 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-01-13 | Alkermes, Inc. | $115 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-01-13 | Alkermes, Inc. | $18 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2021-01-13 | Alkermes, Inc. | $10 | Research payment | In-kind items and services | A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subject | 2021 | |
| 2020-11-19 | Eli Lilly and Company | $1,499 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2020 | |
| 2020-09-01 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-08-01 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-07-30 | Alkermes, Inc. | $3,321 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-07-17 | Eli Lilly and Company | $360 | Research payment | Cash or cash equivalent | AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR | 2020 | |
| 2020-06-25 | Alkermes, Inc. | $20,251 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-06-01 | Alkermes, Inc. | $3,559 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-06-01 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-05-14 | Alkermes, Inc. | $1,270 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-05-08 | Alkermes, Inc. | $3,252 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-05-01 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-04-16 | Alkermes, Inc. | $1,694 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-04-14 | Alkermes, Inc. | $194 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-14 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-14 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-14 | Alkermes, Inc. | $138 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-14 | Alkermes, Inc. | $18 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-13 | Alkermes, Inc. | $194 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-13 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-13 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-13 | Alkermes, Inc. | $18 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-13 | Alkermes, Inc. | $13 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-02 | Alkermes, Inc. | $5,182 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-04-01 | Alkermes, Inc. | $70 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-04-01 | Alkermes, Inc. | $13 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-04-01 | Alkermes, Inc. | $13 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-03-19 | Alkermes, Inc. | $154 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-03-19 | Alkermes, Inc. | $22 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-03-12 | Alkermes, Inc. | $3,901 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-03-02 | Alkermes, Inc. | $3,777 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-27 | Alkermes, Inc. | $2,962 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-02-20 | Alkermes, Inc. | $847 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-02-10 | Alkermes, Inc. | $192 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-10 | Alkermes, Inc. | $115 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-10 | Alkermes, Inc. | $97 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-10 | Alkermes, Inc. | $69 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-10 | Alkermes, Inc. | $42 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-10 | Alkermes, Inc. | $9 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-10 | Alkermes, Inc. | $5 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-03 | Alkermes, Inc. | $3,293 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-02-01 | Alkermes, Inc. | $50 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-01-31 | Eli Lilly and Company | $857 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | 2020 | |
| 2020-01-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,666 | Research payment | Cash or cash equivalent | PoCC dose finding in Mild to Moderate AD | 2020 | |
| 2020-01-24 | Alkermes, Inc. | $375 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2020 | |
| 2020-01-23 | Alkermes, Inc. | $7,230 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-01-23 | Alkermes, Inc. | $2,962 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-01-10 | Alkermes, Inc. | $11,145 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2020 | |
| 2020-01-10 | Alkermes, Inc. | $3,293 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2020 | |
| 2020-01-09 | Alkermes, Inc. | $12,764 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-01-09 | Alkermes, Inc. | $1,694 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-01-09 | Alkermes, Inc. | $1,691 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2020 | |
| 2020-01-02 | Biogen, Inc. | $2,192 | Research payment | Cash or cash equivalent | 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease | 2020 | |
| 2020-01-01 | Alkermes, Inc. | $90 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-01-01 | Alkermes, Inc. | $90 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2020 | |
| 2020-01-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2020 | |
| 2020-01-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2020 | |
| 2019-12-31 | Allergan, Inc. | $12,751 | Research payment | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2019 |
| 2019-12-31 | Allergan, Inc. | $681 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION | 2019 | |
| 2019-12-31 | Allergan, Inc. | $110 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION | 2019 | |
| 2019-12-12 | Alkermes, Inc. | $9,886 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-12-04 | Alkermes, Inc. | $3,911 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-12-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-12-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-11-25 | Genentech, Inc. | $5,772 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PRODROMAL TO MILD AD | 2019 |
| 2019-11-18 | Alkermes, Inc. | $124 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-11-18 | Alkermes, Inc. | $21 | Research payment | In-kind items and services | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-11-07 | Alkermes, Inc. | $12,214 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-11-06 | Alkermes, Inc. | $2,797 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-11-05 | Alkermes, Inc. | $1,936 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2019 | |
| 2019-11-01 | Alkermes, Inc. | $120 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-11-01 | Alkermes, Inc. | $50 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-11-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-11-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-11-01 | Alkermes, Inc. | $12 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-10-31 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2019 | |
| 2019-10-24 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PRODROMAL TO MILD AD | 2019 |
| 2019-10-17 | Alkermes, Inc. | $735 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-10-09 | Genentech, Inc. | $17,032 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PRODROMAL TO MILD AD | 2019 |
| 2019-10-02 | Genentech, Inc. | $400 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PRODROMAL TO MILD AD | 2019 |
| 2019-10-01 | Alkermes, Inc. | $90 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-10-01 | Alkermes, Inc. | $90 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-10-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-10-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-09-30 | Alkermes, Inc. | $1,094 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-09-30 | Alkermes, Inc. | $487 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2019 | |
| 2019-09-30 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2019 | |
| 2019-09-25 | Alkermes, Inc. | $6,323 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-09-25 | Alkermes, Inc. | $1,694 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2019 | |
| 2019-09-03 | Alkermes, Inc. | $2,036 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-09-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-09-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-08-31 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2019 | |
| 2019-08-27 | Alkermes, Inc. | $1,700 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-08-27 | Alkermes, Inc. | $847 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2019 | |
| 2019-08-23 | Alkermes, Inc. | $675 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-08-22 | Eisai Inc. | $16,276 | Research payment | Cash or cash equivalent | Drug | A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lembor | 2019 |
| 2019-08-22 | Eisai Inc. | $941 | Research payment | Cash or cash equivalent | Drug | A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lembor | 2019 |
| 2019-08-08 | Alkermes, Inc. | $2,802 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-08-08 | Alkermes, Inc. | $847 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2019 | |
| 2019-08-08 | Alkermes, Inc. | $625 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-08-06 | Allergan, Inc. | $7,814 | Research payment | Cash or cash equivalent | AN OPEN LABEL, LONG TERM SAFETY STUDY OF RAPASTINEL AS AN ADJUNCTIVE THERAPY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER | 2019 | |
| 2019-08-03 | Alkermes, Inc. | $2,036 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 | |
| 2019-08-03 | Alkermes, Inc. | $1,647 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2019 | |
| 2019-08-01 | Alkermes, Inc. | $50 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-08-01 | Alkermes, Inc. | $40 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-08-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-08-01 | Boehringer Ingelheim RCV GmbH & Co KG | $34 | Research payment | In-kind items and services | PoCC/dose-finding in Mild to Moderate AD | 2019 | |
| 2019-08-01 | Alkermes, Inc. | $12 | Research payment | In-kind items and services | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-07-31 | Alkermes, Inc. | $85 | Research payment | In-kind items and services | A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | 2019 | |
| 2019-07-18 | Alkermes, Inc. | $8,549 | Research payment | Cash or cash equivalent | OLANZAPINE Drug, CNS | A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia | 2019 |
| 2019-07-11 | Alkermes, Inc. | $1,700 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-07-11 | Alkermes, Inc. | $1,268 | Research payment | Cash or cash equivalent | A Phase 3b Extension Study of Adjunctive ALKS5461 in the Treatment of Refractory Major DepressiveDisorder | 2019 | |
| 2019-07-11 | Alkermes, Inc. | $579 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-07-11 | Alkermes, Inc. | $320 | Research payment | Cash or cash equivalent | A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | 2019 | |
| 2019-07-08 | Genentech, Inc. | $3,809 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PRODROMAL TO MILD AD | 2019 |
| 2019-07-02 | Alkermes, Inc. | $3,508 | Research payment | Cash or cash equivalent | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | 2019 |
The latest 200 records of 322.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Redlands, CA, county San Bernardino County, CA, state California; placed by its city name.
| Measure | Place (city or town) Redlands, CA | County San Bernardino County, CA | State California |
|---|---|---|---|
| Population B01003 | 73,375 | 2,197,104 | 39,287,377 |
| Population, 2020 census P1 | 73,168 | 2,181,654 | 39,538,223 |
| Median age B01002 | 34.6 | 34.7 | 37.9 |
| Under 18 B01001 | 23.9% | 25.5% | 22.0% |
| 65 and over B01001 | 14.9% | 12.6% | 15.7% |
| Households B11001 | 25,152 | 674,915 | 13,548,091 |
| Foreign born B05002 | 16.8% | 21.6% | 27.0% |
| Median household income B19013 | $105,041 | $85,478 | $99,122 |
| Median family income B19113 | $116,512 | $93,416 | $113,346 |
| Per capita income B19301 | $49,007 | $34,343 | $49,513 |
| Poverty rate B17001 | 9.1% | 13.3% | 12.0% |
| Unemployment rate B23025 | 5.5% | 7.1% | 6.6% |
| Civilian labor force B23025 | 37,112 | 1,046,624 | 20,068,466 |
| Mean commute (minutes) B08013 | 24.9 | 32.6 | 28.7 |
| Bachelor's degree or higher B15003 | 41.5% | 23.3% | 37.1% |
| Housing units B25001 | 26,256 | 743,886 | 14,644,735 |
| Owner-occupied B25003 | 56.8% | 62.1% | 55.9% |
| Renters B25003 | 43.2% | 37.9% | 44.1% |
| Median home value B25077 | $618,900 | $505,000 | $734,700 |
| Median gross rent B25064 | $2,005 | $1,801 | $2,036 |
| White, not Hispanic B03002 | 40.6% | 24.7% | 33.8% |
| Black B03002 | 5.6% | 7.5% | 5.2% |
| Hispanic or Latino B03002 | 39.5% | 55.2% | 40.2% |
| Asian B03002 | 8.2% | 8.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Redlands, CA.
Comments